It is well documented that human epidermal growth factor receptor 2 (HER2) overexpression/amplification is associated with poor survival in breast cancer patients. However, it is largely unknown whether HER2 somatic mutations are associated with survival in HER2-negative breast cancer patients. Here, we identified HER2 somatic mutations in tumors from 1348 unselected breast cancer patients by sequencing the entire HER2 coding region. All of these mutations were tested for in corresponding blood samples to determine whether they were somatic or germline mutations. We further investigated the associations between HER2 somatic mutations and recurrence-free survival and distant recurrence-free survival in this cohort of patients. We found that 27 of 1348 (2.0%) of these patients carried a HER2 somatic mutation. In vitro experiments indicated that some of the novel mutations and those with unknown functions increased HER2 activity. HER2 status was available for 1306 patients, and the HER2 somatic mutation rates in HER2-positive (n = 353) and HER2-negative breast cancers (n = 953) were 1.4% and 2.3%, respectively. Among the HER2-negative patients, those with a HER2 somatic mutation had a significantly worse recurrence-free survival (unadjusted hazard ratio = 2.67; 95% confidence interval, 1.25-5.72, P = 0.002) and distant recurrence-free survival (unadjusted hazard ratio = 2.50; 95% confidence interval, 1.10-5.68, P = 0.004) than those with wild-type HER2. Taken together, our findings suggested that HER2 somatic mutations occur at a higher frequency in HER2-negative breast cancer, and HER2-negative breast cancer patients with these mutations have poor survival. Therefore, HER2-negative patients with a HER2 somatic mutation are potentially good candidates for HER2-targeted therapy.
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H uman epidermal growth factor 2 is a major proliferative stimulator that activates downstream signaling through the phosphoinositide 3-kinase/AKT and MAPK pathways. (1) (2) (3) (4) (5) Amplification/overexpression of HER2 occurs in 20%-25% of breast cancers, and is associated with poor survival. (6, 7) The use of HER2-targeted drugs, which currently include trastuzumab, pertuzumab, and lapatinib, have dramatically improved the outcomes in HER2-positive breast cancers. (8) (9) (10) (11) (12) (13) Human epidermal growth factor receptor 2 somatic mutations were initially identified in the tyrosine kinase domain of the HER2 gene in breast cancer patients in 2006. (14) Recently, such mutations have been identified in HER2-negative breast cancer patients by sequencing assays, including whole-cancer genome sequencing. (14) (15) (16) (17) (18) (19) (20) (21) Although the mutation rate of this gene is very low (<2%), in vitro and in vivo experiments have shown that some somatic mutations can activate the HER2 signaling pathway in HER2-negative cells and that these cells are sensitive to some HER2-targeted drugs. (22) (23) (24) (25) These findings suggest that HER2 somatic mutations represent an alternative mechanism for the activation of HER2 in HER2-negative breast cancers, raising an interesting question of whether somatic mutations in HER2-negative breast cancer patients influence the clinical outcome. Therefore, the purposes of this study were as follows: (i) to identify HER2 somatic mutations in tumor tissues from a large cohort of 1348 patients; (ii) to investigate whether the somatic mutations with novel or unknown functions identified in this study affect HER2 function by undertaking in vitro experiments; and (iii) to investigate whether HER2 somatic mutations influence patient survival in the entire study population and, specifically, in HER2-negative breast cancer patients.
Materials and Methods
Patients. From November 2003 to July 2012, fresh-frozen tumor tissues were obtained by core-needle biopsy prior to therapy or were procured during surgery from 1496 primary breast cancer patients (stages I-III) at the Breast Center, Peking University Cancer Hospital (Beijing, China). Human epidermal growth factor receptor 2 somatic mutation status was successfully determined in 1348 of these patients. Tumor stage was classified according to the TNM classification of the Union for International Cancer Control. Tumor size was defined as the maximum tumor diameter as measured by ultrasound at the time of diagnosis. Tumors were graded histologically according to the modified Bloom-Richardson grading system. This study was carried out in accordance with the ethics principles of the Declaration of Helsinki and approved by the Research and Ethics Committee of Peking University Cancer Hospital. All patients provided written informed consent.
Analysis of HER2 mutations in tumor tissue. Tumor samples were obtained by core-needle biopsy or at the time of surgery and immediately stored at À80°C. Total RNA was extracted using TRIzol reagent (Life Technologies, Gaithersburg, MD, USA) and reverse-transcribed to cDNA using the standard procedure. The complete HER2 coding sequence was amplified with nine sets of primers. All fragments were sequenced using a BigDye Terminator Cycle Sequencing Kit and an ABI3730 automated sequencer (Applied Biosystems, Foster City, CA, USA). All sequence variants were confirmed in duplicate.
Analysis of HER2 germline mutations. Genomic DNA was extracted from peripheral blood leukocytes using a Whole Blood Genome DNA Isolation Kit (Bioteke, Beijing, China). Patients with a HER2 mutation in their breast tumor were further investigated to determine whether the mutation was present in their blood DNA.
Estrogen receptor, PR, and HER2 status. Estrogen receptor, PR, and HER2 status were determined using breast cancer tissue obtained from the core-needle biopsy or tumor tissues after surgery. Estrogen receptor or PR immunostaining was considered positive when ≥1% of tumor cells showed positive nuclear staining. The HER2 staining was scored according to the standard method. Scores of 0 and 1+ were considered negative, and a score of 3+ was considered positive. If a score was 2+, we further evaluated the HER2 status using FISH (Vysis, Downers Grove, IL, USA) of core biopsies according to the manufacturer's instructions.
Functional characterization of somatic HER2 mutations in vitro. MCF-7 (human breast cancer cells) and HEK293T (human embryonic kidney cells) cells were recultured in DMEM (HyClone, Logan, UT, USA) with 10% FBS (HyClone). The HER2
WT -pXJ40-myc plasmid was kindly provided by Dr. Qinong Ye (Academy of Military Medical Sciences, Beijing, China). Fifteen missense mutations (L12R, E139G, E139D, A466V, C515R, T526A, L755S, G776R, S783P, T862R, L869R, P885S, R897G, F1030C, and P1074S) were introduced by site-directed mutagenesis and confirmed by sequencing. V777L, a well-characterized activating mutation, served as a positive control. Transient transfection of the plasmids into the MCF-7 and HEK293T cells was carried out using VigoFect (Vigorous Biotechnology, Beijing, China), according to the manufacturer's protocol. After 24 h, the cells were washed twice with 1 9 PBS and starved in serum-free medium for another 12 h.
The following antibodies were used: AKT (C67E7), phospho-AKT (Ser473) (D9E), ERK1/2 (137F5), and phospho-ERK1/2 (Thr202/Tyr204) (D13.14.4E) (Cell Signaling Technology, Boston, MA, USA). Phospho-HER2 (pY1248, 06-229) was from Millipore (CA, USA); HER2 (C-18) and GAPDH (FL-335) were from Santa Cruz Biotechnology (CA, USA). GAPDH was used as a protein loading control. The relative intensities of individual protein bands were quantified by analysis of digitized images using ImageJ software (https://imagej. nih.gov/ij/download.html). For the phospho-specific detection of proteins, the acquired density was compared with the corresponding total antibody signal. All data shown are representative of at least three experiments.
Statistical analysis. Differences in clinicopathological characteristics between patients with a HER2 somatic mutation and those with wild-type HER2 were determined using Pearson's chi-square-test or Fisher's exact test. Survival curves were generated and compared using the Kaplan-Meier method and Breslow tests. Recurrence-free survival was calculated from the time of diagnosis to the first recurrence (local or distant) or death from breast cancer (for patients without a recorded relapse) or to the date of the last follow-up. Distant recurrence-free survival was calculated from the time of diagnosis to the first distant metastasis or death from breast cancer (for patients without a recorded relapse) or to the date of the last follow-up. The Cox proportional hazards model was used to determine the association of HER2 somatic mutation status with the risk of local or distant recurrence after adjustments for patient and tumor characteristics. Two-sided P-values less than 0.05 were considered statistically significant. All analyses were carried out using SPSS 20.0 software (Chicago, IL, USA).
Results
Somatic mutations in the HER2 gene. A total of 33 patients carried HER2 mutations in their tumor tissues in this cohort of 1348 breast cancer patients (Table S1 ). Four patients had two HER2 mutations, resulting in a total of 37 mutations in 33 patients. The mutations in seven patients (one of the seven patients also had a somatic HER2 mutation) were also present in the corresponding blood DNA samples, indicating that they were germline (Table S1 ). The remaining 30 mutations (27 patients) were absent from matched blood samples, indicating that they were somatic (Table S1 ). Thus, we finally confirmed that 27 of 1348 patients (2.0%) carried a HER2 somatic mutation in this cohort (Table 1) . Information regarding HER2 status was available for 1306 of the 1348 patients in this study. Of these, 353 (27.0%) were HER2-positive, and 953 (73.0%) were HER2-negative ( Table 2) . Among the 27 patients with a HER2 somatic mutation, the frequencies of these mutations in those with HER2-negative and HER2-positive breast cancers were 2.3% (22/ 953) and 1.4% (5/353), respectively.
HER2 somatic mutations were not significantly associated with tumor size, tumor grade, lymph node status, ER, PR, or HER2 status. However, patients with a HER2 somatic mutation were older than those with wild-type HER2 (Table 2) . Trastuzumab use, adjuvant chemotherapy, and breast-conserving therapy did not significantly differ between the patients with a HER2 somatic mutation and those with wild-type HER2 ( Table 2) .
The majority of patients with a HER2 mutation had missense mutations (92.6%, 25/27), and only two showed the same insertion mutation (A775_G776insYVMA). Examination of the locations of the somatic mutations in the HER2 domains revealed that they were clustered into two major areas: 37.0% of the patients (10/27) had an ECD mutation and 55.6% (15/27) had a KD mutation (Fig. 1) . Five recurrent mutations, V777L, S310F, L755S, A775_G776insYVMA, and L869R, were found in this cohort ( Table 1 ). Sixteen of the 27 patients (59.3%) carried a recurrent mutation ( Table 1 ). All five recurrent mutations have been reported previously, and all were located in the KD, with the exception of S310F (Fig. 1) . Fig. 1 ). Of these, 18 have been reported previously (22, 26, 27) and 12 are novel (Fig. 1) . Based on published reports, (22, 26, 27) we estimated that at least 13 of the 27 patients carried an activating HER2 mutation that was likely to be a driver event in breast cancer ( Table 1 ). The functional effects of the remaining 15 mutations were not determined or were not fully elucidated. We therefore further characterized these mutations by undertaking in vitro experiments.
Functional analyses of novel and unknown mutations in vitro. The level of P-HER2 was markedly higher in MCF-7 cells with C515R, T526A, G776R, L755S, A466V, T862R, and P1074S mutations than in cells with wild-type HER2 (Fig. 2a,Fig. S1a) . No significant differences were observed in the level of P-HER2 between cells with the remaining mutations and wild-type HER2 (Fig. 2a,Fig. S1a) . In HEK293T cells, the C515R, A466V, T862R, L869R, and R897G mutations strongly increased the level of P-HER2 (Fig. 2b,  Fig. S1b) . The C515R mutation also increased the levels of P-ERK and P-AKT (Fig. 2b) . In addition, the L12R, T526A, and G776R mutations increased the level of P-ERK but had little effect on P-HER2 and P-AKT levels. The L755S mutation increased the phosphorylation of ERK and AKT but decreased the phosphorylation of HER2 (Fig. 2b) . These results showed that the C515R, A466V, and T862R mutations increased HER2 activity in both cell lines, suggesting that they are activating mutations. The T526A, G776R, L755S, L869R, R897G, and P1074S mutations increased HER2 activity in either MCF-7 or HEK293T cells, suggesting that they are also activating mutations. The other mutations (L12R, E139G, E139D, S783P, P885S, and F1030C) seemed to be neutral. Thus, nine of the 15 mutations are activating mutations.
HER2 somatic mutations and survival in the entire study cohort. To investigate the association between survival and HER2 somatic mutations, a total of 1348 breast cancer patients were evaluated. The median length of follow-up was 60 months (range, 1-116 months). Two hundred and sixteen patients experienced recurrence (local or distant) or died of breast cancer in this cohort of patients during the follow-up period.
Patients with HER2 mutations had a significantly worse RFS (unadjusted HR = 1.91; 95% CI, 0.90-4.05, P = 0.025; HER2 somatic mutations and survival in HER2-negative breast cancer patients. HER2 somatic mutations were detected at a higher frequency in HER2-negative breast cancer patients. HER2-negative patients with a HER2 somatic mutation (n = 22) had a significantly worse RFS (unadjusted HR = 2.67; 95% CI, 1.25-5.72, P = 0.002; Fig. 3a) and DRFS (unadjusted HR = 2.50; 95% CI, 1.10-5.68, P = 0.004; Fig. 3b ) than those with wild-type HER2 (n = 953). Multivariate analysis revealed that HER2 somatic mutation was a borderline unfavorable factor for RFS (HR = 2.47; 95% CI, 0.99-6.16, P = 0.051) (Table S2) , and it was also a non-significantly unfavorable factor for DRFS (HR = 2.29; 95% CI, 0.92-5.70, P = 0.075) (Table S2) after adjusting for age, lymph node, tumor size, tumor grade, ER, PR, and HER2 status.
Only five patients with a HER2 somatic mutation were HER2-positive, and none of them received trastuzumab treatment. Given the small sample size, we did not undertake survival analysis in this subgroup.
Discussion
In this study, by sequencing tumor cDNA, we found that 27 patients (2.0%) carried a HER2 somatic mutation in a cohort of 1348 operable primary breast cancer patients. These mutations were more common in HER2-negative breast cancer patients (2.3%) than in those who were HER2-positive (1.4%). HER2-negative patients with a HER2 somatic mutation had a significantly worse survival than those with wild-type HER2.
All of the recurrent mutations identified in this study have been previously reported, and of these, V777L, S310F, and A775_G776insYVMA were determined to be activating mutations. (22, 26, 27) Four of the five recurrent mutations were located in the KD, and S310F was localized to the ECD. The five recurrent mutations and other mutations in the KD accounted for 74.1% (20/27) of the mutations in this study. Therefore, screening for recurrent mutations and mutations in the KD is a fast and effective assay to quickly detect HER2 somatic mutations in breast cancer patients.
We also identified 12 novel mutations, which were located throughout the entire gene. Functional analysis of the novel mutations and those with unknown function (a total of 15 mutations) showed that 9 of the 15 mutations activated the HER2 signaling pathway. Our findings, and those of previous reports, (22, 26, 27) suggest that the majority of HER2 somatic mutations are disease-associated.
In this study, we also found six HER2 germline mutations (R157W, A466V, K681N, R849W, R1146W, and E1195G) in seven breast cancer patients. Among them, R157W was previously reported as a somatic mutation, (28) which was found in micropapillary urothelial carcinoma located in the ECD and was predicted to be pathogenic by FATHMM prediction (Cosmic database). The A466V mutation was also determined as somatic in this cohort and increased HER2 activity in MCF-7 and HEK293T cell lines. The remaining germline mutations (K681N, R849W, R1146W, and E1195G) were novel and need further functional studies.
Clinically, HER2-negative breast cancers are not typically treated with HER2-targeted therapy. Recent studies have suggested that the HER2-targeted drugs trastuzumab and lapatinib inhibit the growth of cells with HER2 somatic mutations in vitro and in vivo. (22) (23) (24) In addition, neratinib, a novel HER2-targeted drug, has shown a strong inhibitory effect in patients with a HER2 somatic mutation. (22, 29, 30) Therefore, given the poor survival of HER2-negative breast cancer patients who carry a HER2 somatic mutation, they are good candidates for receiving HER2-targeted therapy or for recruitment into ongoing clinical trials. In addition, five HER2-positive patients carried an activating HER2 somatic mutation. Two of them had contralateral breast cancer and one died from suicide. Given the small sample size, we did not undertake survival analysis in the HER2-positive subgroup.
The 2.3% somatic mutation rate in HER2-negative breast cancer patients was remarkable, considering that 70%-80% of all patients had HER2-negative breast cancer. Therefore, it will not be difficult to gather enough patients for clinical trials. HER2-negative patients had a generally favorable survival compared with the HER2-positive patients, and when the HER2-negative patients were grouped according to the presence/absence of a HER2 somatic mutation, those without a somatic mutation had better survival.
In summary, we found that HER2 somatic mutations occurred more frequently in the HER2-negative breast cancer patients compared with those with HER2-positive breast cancer, and that approximately 2.3% of these HER2-negative patients harbored a HER2 somatic mutation. HER2-negative patients carrying a HER2 somatic mutation were determined to have an unfavorable outcome. Therefore, HER2-negative patients with this type of mutation are potentially good candidates for HER2-targeted therapy.
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